You are here: Industry Insights > Allergan

News List

Exasperated Allergan investors recruiting activists to push for asset sales fiercepharma
April 28, 2018
Investors aren’t happy with the steps Allergan has taken to try to remedy its share-price slump—and they’re calling on outsiders to help stir things up.
Allergan says not interested in buying Shire pharmaphorum
April 23, 2018
Allergan has said it is not interested in buying Shire after all, after announcing yesterday that it was considering a bid for the UK-listed firm also targeted by Takeda.
Shire Rejects Takeda’s $60 Billion Acquisition Bid and Allergan Reportedly In Talks with Shire biospace
April 20, 2018
According to Reuters UK, Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.
Allergan launches Ozurdex in China biospectrumasia
March 23, 2018
Allergan introduces Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of retinal vein occlusion (RVO)
Allergan navigating choppy waters, as shares rise and fall pharmafile
March 19, 2018
By most measures Allergan has not had the most successful of years and one measure, in particular, is usually indicative of a company’s performance, share price.
Allergan to acquire Australian biotech startup Elastagen biospectrumasia
February 11, 2018
Elastagen’s revolutionary technology is based on recombinant human tropoelastin, the precursor of elastin which is a key component of youthful skin
Why Pfizer Could and Should Make Another Move on Allergan biospace
January 10, 2018
Should Pfizer make another play at acquiring Allergan? At least one analyst thinks the move would be a good one for the pharma giant.
Allergan to cut 1,000+ Jobs biospace
January 05, 2018
Allergan will cut 1,000 jobs, about 5% of the total workforce
Allergan, Richter Announce Positive Results in Cariprazine Study americanpharmaceuticalreview
December 19, 2017
Allergan and Gedeon Richter announced positive topline results for a phase 3 study of cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar I depression).
Allergan could sell women's health for $6B, if it would only agree to split: analyst fiercepharma
November 21, 2017
RBC Capital Markets analyst Randall Stanicky sees lots of reasons Allergan should pursue a breakup. A women’s health sale that could bring in billions is just one of them.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page